Comparative Pharmacology
Head-to-head clinical analysis: NUMORPHAN versus ROXILOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUMORPHAN versus ROXILOX.
NUMORPHAN vs ROXILOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist; binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Intravenous or subcutaneous: 0.5-2 mg (0.1-0.2 mg/kg for severe pain) every 2-3 hours as needed; not to exceed 20 mg/day.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours in adults; prolonged to 3–4 hours in elderly and up to 15 hours in patients with severe hepatic impairment.
Terminal elimination half-life 4.5 hours; prolonged to 18-24 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal (approximately 70% as unchanged drug, <5% as noroxymorphone and other conjugates); biliary/fecal excretion accounts for ~20%.
Renal (70-80% unchanged), biliary/fecal (15-20%), remainder metabolized
Category C
Category C
Opioid Analgesic
Opioid Analgesic